These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24439904)

  • 1. Sema4A inhibits the therapeutic effect of IFN-β in EAE.
    Koda T; Okuno T; Takata K; Honorat JA; Kinoshita M; Tada S; Moriya M; Sakoda S; Mochizuki H; Kumanogoh A; Nakatsuji Y
    J Neuroimmunol; 2014 Mar; 268(1-2):43-9. PubMed ID: 24439904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis.
    Nakatsuji Y; Okuno T; Moriya M; Sugimoto T; Kinoshita M; Takamatsu H; Nojima S; Kimura T; Kang S; Ito D; Nakagawa Y; Toyofuku T; Takata K; Nakano M; Kubo M; Suzuki S; Matsui-Hasumi A; Uto-Konomi A; Ogata A; Mochizuki H; Sakoda S; Kumanogoh A
    J Immunol; 2012 May; 188(10):4858-65. PubMed ID: 22491253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sema4A as a biomarker predicting responsiveness to IFN β treatment].
    Nakatsuji Y
    Rinsho Shinkeigaku; 2014; 54(12):972-4. PubMed ID: 25519959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    Koda T; Namba A; Nakatsuji Y; Niino M; Miyazaki Y; Sugimoto T; Kinoshita M; Takata K; Yamashita K; Shimizu M; Fukazawa T; Kumanogoh A; Mochizuki H; Okuno T
    PLoS One; 2018; 13(3):e0193986. PubMed ID: 29518148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase.
    Koda T; Namba A; Kinoshita M; Nakatsuji Y; Sugimoto T; Sakakibara K; Tada S; Shimizu M; Yamashita K; Takata K; Ishikura T; Murata S; Beppu S; Kumanogoh A; Mochizuki H; Okuno T
    J Neuroinflammation; 2020 Mar; 17(1):82. PubMed ID: 32169103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
    Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
    Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration.
    Schmidt J; Stürzebecher S; Toyka KV; Gold R
    J Neurosci Res; 2001 Jul; 65(1):59-67. PubMed ID: 11433430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE.
    Isaksson M; Ardesjö B; Rönnblom L; Kämpe O; Lassmann H; Eloranta ML; Lobell A
    Eur J Immunol; 2009 Oct; 39(10):2925-35. PubMed ID: 19637225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor α signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis.
    Lélu K; Laffont S; Delpy L; Paulet PE; Périnat T; Tschanz SA; Pelletier L; Engelhardt B; Guéry JC
    J Immunol; 2011 Sep; 187(5):2386-93. PubMed ID: 21810607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis.
    Fitzgerald DC; Fonseca-Kelly Z; Cullimore ML; Safabakhsh P; Saris CJ; Zhang GX; Rostami A
    J Immunol; 2013 Apr; 190(7):3225-34. PubMed ID: 23455508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in multiple sclerosis and EAE.
    Campbell SJ; Meier U; Mardiguian S; Jiang Y; Littleton ET; Bristow A; Relton J; Connor TJ; Anthony DC
    Brain Behav Immun; 2010 Jul; 24(5):738-46. PubMed ID: 20138139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment.
    Castro SB; Junior CO; Alves CC; Dias AT; Alves LL; Mazzoccoli L; Mesquita FP; Figueiredo NS; Juliano MA; Castañon MC; Gameiro J; Almeida MV; Teixeira HC; Ferreira AP
    Int Immunopharmacol; 2012 Feb; 12(2):465-70. PubMed ID: 22245971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells.
    Sonobe Y; Li H; Jin S; Kishida S; Kadomatsu K; Takeuchi H; Mizuno T; Suzumura A
    J Immunol; 2012 Mar; 188(6):2602-11. PubMed ID: 22323540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salmon proteoglycan suppresses progression of mouse experimental autoimmune encephalomyelitis via regulation of Th17 and Foxp3(+) regulatory T cells.
    Sashinami H; Asano K; Yoshimura S; Mori F; Wakabayashi K; Nakane A
    Life Sci; 2012 Dec; 91(25-26):1263-9. PubMed ID: 23069584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive and therapeutic effects of adenanthin on experimental autoimmune encephalomyelitis by inhibiting NF-κB signaling.
    Yin QQ; Liu CX; Wu YL; Wu SF; Wang Y; Zhang X; Hu XJ; Pu JX; Lu Y; Zhou HC; Wang HL; Nie H; Sun HD; Chen GQ
    J Immunol; 2013 Sep; 191(5):2115-25. PubMed ID: 23964105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE).
    Li Z; Chen L; Niu X; Liu J; Ping M; Li R; Xie X; Guo L
    J Neuroimmunol; 2012 Sep; 250(1-2):9-17. PubMed ID: 22673299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulatory molecule expression on leukocytes from mice with experimental autoimmune encephalomyelitis treated with IFN-beta.
    Hallal DE; Farias AS; Oliveira EC; Diaz-Bardales BM; Brandão CO; Protti GG; Pereira FG; Metze IL; Santos LM
    J Interferon Cytokine Res; 2003 Jun; 23(6):293-8. PubMed ID: 12859855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis.
    Murphy AC; Lalor SJ; Lynch MA; Mills KH
    Brain Behav Immun; 2010 May; 24(4):641-51. PubMed ID: 20138983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARδ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis.
    Kanakasabai S; Walline CC; Chakraborty S; Bright JJ
    Brain Res; 2011 Feb; 1376():101-12. PubMed ID: 21192919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.